Home
All Resources

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry

Written by Samantha Schwab

Updated: Apr 11, 2021

Authors
More from the author

By Jamie Weissglass

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry, Screenshot, Front Page

The pharmaceutical industry is experiencing heightened merger and acquisition activity, due in large part to rising competition, increasing regulatory challenges and expiring patents’ periods of exclusivity. In 2018, the industry saw 248 mergers worth approximately $198 billion; one law firm predicts that the value of transactions will soar to $331 billion in 2019.

In the course of these transactions, many pharmaceutical companies have encountered information governance challenges that they did not anticipate—or budget for—prior to the merger. As they begin to assess the disparate data source landscapes in an effort to unify their systems, issues in their document retention, preservation and retrieval become readily apparent, requiring a substantial amount of time and monetary investment to resolve—resources that are typically scarce after a transaction closes. This generally means that the necessitated data mapping, remediation and integration endeavors are deprioritized, leaving these combined organizations even more exposed in the event of litigation or a regulatory or compliance investigation.

This white paper takes a closer look at the status of mergers and acquisitions in the pharmaceutical industry, the challenges that these transactions exacerbate for the combined companies and solutions for mitigating those risks.

Read the Full Whitepaper.

By Jamie Weissglass

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry, Screenshot, Front Page

The pharmaceutical industry is experiencing heightened merger and acquisition activity, due in large part to rising competition, increasing regulatory challenges and expiring patents’ periods of exclusivity. In 2018, the industry saw 248 mergers worth approximately $198 billion; one law firm predicts that the value of transactions will soar to $331 billion in 2019.

In the course of these transactions, many pharmaceutical companies have encountered information governance challenges that they did not anticipate—or budget for—prior to the merger. As they begin to assess the disparate data source landscapes in an effort to unify their systems, issues in their document retention, preservation and retrieval become readily apparent, requiring a substantial amount of time and monetary investment to resolve—resources that are typically scarce after a transaction closes. This generally means that the necessitated data mapping, remediation and integration endeavors are deprioritized, leaving these combined organizations even more exposed in the event of litigation or a regulatory or compliance investigation.

This white paper takes a closer look at the status of mergers and acquisitions in the pharmaceutical industry, the challenges that these transactions exacerbate for the combined companies and solutions for mitigating those risks.

Read the Full Whitepaper.

Fill out the form below to download the complete insight.

Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Åland Islands
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Sign up for Consilio updates

Discover, learn and grow with the latest insights from Consilio
Thank you! Your submission has been received!
By clicking Subscribe you are confirming that you agree with our Privacy Policy
Oops! Something went wrong while submitting the form.